A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants with Congenital Protein C Deficiency

Launched by TAKEDA · Sep 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Freeze-dried Human Protein C Concentrate, or TAK-662, for people with a condition known as congenital protein C deficiency. This condition means the body does not produce enough protein C, which is important for blood clotting. The main goal of the study is to see how well TAK-662 works and to monitor any side effects that might occur during treatment.

If you or a family member has congenital protein C deficiency and are interested in participating, you may be eligible as there are no specific exclusion criteria. Participants will receive TAK-662 through an intravenous (IV) injection, and the researchers will observe and record any effects for up to 24 months. This study is currently recruiting participants of all ages and genders, and it aims to gather valuable information about the safety and effectiveness of this treatment for those living with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - All participants with congenital protein C deficiency who are administered with Freeze-dried Human Protein C Concentrate (TAK-662).
• Exclusion Criteria:
• • - None